Insights

Pediatric chronic hepatitis B and C treatments differ from adults, with specific approved therapies for different age groups. Early intervention and regular screening are key to preventing severe liver disease complications in children.

Area of Science:

  • Pediatric Gastroenterology and Hepatology
  • Viral Hepatitis Treatment

Background:

  • Chronic hepatitis B and C in children exhibit distinct natural histories and therapeutic guidelines compared to adults.
  • Current approved treatments for chronic hepatitis B in children under twelve include interferon alfa and lamivudine; older children may also use tenofovir and adefovir.

Purpose of the Study:

  • To outline current therapeutic strategies and goals for managing chronic viral hepatitis in pediatric populations.
  • To emphasize the importance of age-specific treatment protocols and risk-factor assessment for optimizing outcomes.
  • To highlight the necessity of regular hepatocellular carcinoma screening in children with chronic viral hepatitis.

Main Methods:

  • Review of existing treatment guidelines and approved therapies for pediatric chronic hepatitis B and C.
  • Analysis of disease progression and complication risks in children versus adults.
  • Discussion of treatment indications, therapeutic goals, and monitoring strategies.

Main Results:

  • Treatment for chronic hepatitis B in children is age-dependent, with monotherapy options available.
  • Chronic hepatitis C treatment in children is reserved for progressive disease, typically involving pegylated interferon alfa 2b and ribavirin.
  • Annual screening for hepatocellular carcinoma is recommended for all children with chronic viral hepatitis due to elevated risk.

Conclusions:

  • Tailored therapeutic approaches are essential for managing chronic viral hepatitis in children.
  • Treatment aims to halt disease progression and mitigate long-term risks like cirrhosis and cancer.
  • Vigilant monitoring, including regular cancer screening, is crucial for improving pediatric outcomes.

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
80
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
21
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
401
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
57
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
405
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
96